CYLD and gastric adenocarcinoma: Notably, a study by Ghadami et al. which used 53 tumor tissues and their non-neoplastic control counterparts to study the CpG island methylation expression level of lysine 63 deubiquitinase (CYLD) gene promoter in gastric adenocarcinoma revealed that the expression level of CYLD mRNA was significantly decreased in females [Male: 95% CI −0.1451 to 0.2651, p = 0.5622; Female: 95% CI 0.2709 to 0.8891, p = 0.001] [20].